Ecopia BioSciences Inc.
TSX : EIA

Ecopia BioSciences Inc.

September 28, 2005 11:18 ET

Ecopia's DECIPHER'R' Technology Produces 40 New Discoveries

MONTREAL, QUEBEC--(CCNMatthews - Sept. 28, 2005) - Ecopia BioSciences Inc. (TSX:EIA) is pleased to announce that its discovery team has increased the Company's count of new chemical entities ("NCEs") from 19 to 59. These NCEs were discovered by Ecopia's scientists in the twelve month period ended September 28, 2005, using the Company's proprietary DECIPHER® technology. Altogether, these new molecules represent more than 26 families of new chemical classes, showing the ability of the DECIPHER® technology to provide Ecopia with a wide diversity of innovative drug candidates.

The most advanced of all these discoveries is ECO-4601, a small molecule with anticancer activity that crosses the blood brain barrier and is being developed, first, for the treatment of primary brain tumor. Ecopia's management expects to file its first regulatory package by the end of 2005, supporting the use of ECO-4601 in a Phase I clinical trial in early 2006.

From its portfolio of 59 NCEs discovered using its DECIPHER® technology, at least 14 have shown anticancer activities. Ecopia's scientists are now investigating these novel anticancer compounds in order to identify at least one other NCE that could form the basis of a second regulatory filing.

"Using our DECIPHER® technology to fight cancer has become our vocation at Ecopia and its start with bringing ECO-4601 as soon as possible into the clinic", commented Pierre Falardeau, President and Chief Executive Officer. He added, "The results we are getting so far with ECO-4601 validate our ability to discover drugs with significant therapeutic potential.".

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to move our flagship compound ECO-4601 into Phase I clinical trials. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary tumor growth in the brain and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the Decipher® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at www.ecopiabio.com.

This press release may contain forward-looking statements that reflect the Company's current expectations regarding future events. The forward-looking statements, including expectations as to the pharmaceutical potential of ECO-4601, the timeframe for its preclinical and clinical development into a new medication, and expansion of the Company's product pipeline involve risk and uncertainties. Actual events could differ materially from those projected here and depend on a number of factors, including scientific uncertainties relating to scientific hypotheses and experimental approaches in regard to drug discovery p, uncertainties related to the regulatory process for drug development and the success and timely completion of clinical studies and trials, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in Ecopia's 2004 Annual Report.

Contact Information